Q2 Results Remove Uncertainty in Hi Tech Pharmacal (HITK)

Article Related Press Releases (1) Related Articles (1) Stock Quotes (1) Comments (0)

Yesterday Hi Tech Pharmacal (NASDAQ: HITK) reported Q2 earnings that topped estimates and, in the view of analysts at Canaccord Genuity, "brings upside and removes the uncertainty".

"HITK reported upside to fiscal 2Q results driven by solid revenue trends and sequential improvement in gross margin, reversing the recent pullback on concerns related to the quarter," said analyst Randall Stanicky.

He thinks sources of penitential upside include a strong cough and cold season, pipeline surprises, lack of competition for Fluticasone, and the company's strong cash position.

"HITK currently trades at 5.1x EV/EBITDA (ex special dividend) which we think is attractive given the high-barrier and strategic nature of the asset base," said Stanicky.

Canaccord Genuity has a Buy rating on Hi Tech Pharmacal (NASDAQ: HITK) and a price target of $42.00.

For an analyst ratings summary and ratings history on Hi Tech Pharmacal click here. For more ratings news on Hi Tech Pharmacal click here.

Shares of Hi Tech Pharmacal closed at $35.25 yesterday, with a 52 week range of $27.35-$43.08.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Morgan Stanley Maintains Bullish Stance on Walter Energy (WLT)
• Adobe (ADBE) Posts Positive Creative Cloud Subscriber Surprise in Q2 - Jefferies
• Gabelli Downgrades Nexstar Broadcasting Group (NXST) to Hold

Create E-mail Alert Related Categories

Analyst Comments, Analyst EPS View

Related Entities

Dividend, Earnings, Canaccord Genuity

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?